Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1.
Successful treatment of human immunodeficiency virus infection may ultimately require targeting of hematopoietic stem cells. Here we used retroviral vectors carrying the ribozyme gene to transduce CD34+ cells from human fetal cord blood. Transduction and ribozyme expression had no apparent adverse effect on cell differentiation and/or proliferation. The macrophage-like cells, differentiated from the stem/progenitor cells in vitro, expressed the ribozyme gene and resisted infection by a macrophage tropic human immunodeficiency virus type 1. These results suggest the feasibility of stem cell gene therapy for human immunodeficiency virus-infected patients.
Yu
M
M
Department of Medicine, University of California, San Diego, La Jolla 92093-0665.
Leavitt
M C
MC
Maruyama
M
M
Yamada
O
O
Young
D
D
Ho
A D
AD
Wong-Staal
F
F
D015703:Antigens, CD / Q000032:analysis*; D018952:Antigens, CD34; D001483:Base Sequence; D002454:Cell Differentiation; D002455:Cell Division; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D004258:DNA Polymerase III / Q000235:genetics; D005312:Fetal Blood / Q000166:cytology; D005822:Genetic Vectors; D015497:HIV-1 / Q000502:physiology*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D018189:Immunomagnetic Separation; D008264:Macrophages / Q000821:virology*; D008969:Molecular Sequence Data; D011401:Promoter Regions, Genetic / Q000235:genetics; D016337:RNA, Catalytic / Q000096:biosynthesis / Q000235:genetics*; D012190:Retroviridae; D014170:Transformation, Genetic; D014779:Virus Replication
D015703:Antigens, CD; D018952:Antigens, CD34; D016337:RNA, Catalytic; D004258:DNA Polymerase III